PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2

puracath • Mar 19, 2020

President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an average of a 3% death rate. Every U.S. state, other than West Virginia, has confirmed cases of COVID-19. This link 1 has the most up to date information on total COVID-19 confirmed cases and deaths. One of the dangers is that the onset of symptoms can occur up to 14 days after exposure, which may vary with age and other underlying health conditions. The Center for Disease Control (CDC) says that one can acquire COVID-19 by being 6 feet away from an infected person if they do not have personal protective equipment.

PuraCath’s Firefly TM disinfection technology has been successfully tested on other resistant and deadly microorganisms like Methicillin Resistant Staphyloccus Aureus (MRSA) and Candida Auris and proven to reduce 99.99% of those microorganisms with only 1 second of Firefly TM UV light. Moreover, in a study published by Cheng et al 2 , UV germicidal irradiation (UVGI) was shown to effectively inactivate encapsulated coronavirus (like SARS, MERS, SARS CoV-2) and H5N1 virus. The wavelengths of UV-C that prove germicidal effect are between 185 nm to 285 nm and the same to the wavelengths used in the Firefly TM disinfection technology. As such, PuraCath’s standard protocols should be sufficient to eliminate 99.99% of SARS CoV-2.

The PuraCath Firefly device can help utilize UV light to protect nurse-to-patient or patient-to-patient transmission of the SARS CoV-2 in patients with Midlines, PICC, CVC, or IV lines ($3.6B+ US market). These patients can be at home or in hospitals and typically in the ICU. Moreover, these are typically immunocompromised or immunosuppressed patients who are most susceptible to acquire SARS CoV-2 and experience higher fatality rates.

Besides the Firefly TM , PuraCath is also working on expanding its platform to other devices to help patients and consumers protect themselves from viruses like the SARS CoV-2.

  1. https://www.seedinvest.com/puracath.medical/series.a
  2. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
  3. Cheng, Nelson & Moe, Patrick & valdez salas, Benjamin & Beltrán-Partida, Ernesto & Nedev, Nicola. (2020). Inactivation of Enveloped Viruses (Coronavirus, H5N1 Virus) and Disinfection of the Air with Legionella-X 100 Via Ultraviolet Germicidal Irradiation (UVGI).
PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access
By puracath 03 Aug, 2021
Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting. PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™ Needleless Connector from the U.S. Food […]
Why We Aren’t Using UV to Disinfect Everything—Yet
By puracath 16 Jun, 2020
Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]
PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second
By puracath 27 Apr, 2020
PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]
By puracath 19 Jun, 2019
JUNE 18, 2019 PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans. “Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV […]
By puracath 07 Mar, 2017
San Francisco, California (March 7, 2017) – PuraCath Medical has published the result of its recent research on its ultraviolet (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal of the International Society for Peritoneal Dialysis. PDI is a major source of knowledge in the field of peritoneal dialysis and aims […]
PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System durin
By Larry Yost 12 May, 2016
San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]
PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings
By Larry Yost 28 Apr, 2016
Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]
PuraCath Medical Presents New Research Data during 36th Annual Dialysis Conference
By Larry Yost 29 Feb, 2016
Company presents study on the effectiveness of next-generation version of the FireFly™ Peritoneal Dialysis Connector Disinfecting System Seattle, Washington (February 29, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of […]
PuraCath Medical Receives 510(k) Clearance for the FireFly™ Peritoneal Dialysis Connector Disinfecti
By puracath 26 Jan, 2016
PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it has received 510(k) clearance for its FireFly™ Peritoneal Dialysis Connector Disinfecting System from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives PuraCath clearance to market […]
By puracath 22 Oct, 2015
We are excited to announce that PuraCath Medical is listed as a start-up to watch in the latest volume of the MedTech Strategist published on October 16th.  Please read the full article here.
More Posts
Share by: